{"id":"travoprost-004-sterile-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Conjunctival hyperemia"},{"rate":"10-25","effect":"Iris pigmentation increase"},{"rate":"10-20","effect":"Eyelash growth (hypertrichosis)"},{"rate":"5-15","effect":"Eye irritation/discomfort"},{"rate":"5-10","effect":"Foreign body sensation"}]},"_chembl":{"chemblId":"CHEMBL1200799","moleculeType":"Small molecule","molecularWeight":"500.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Travoprost mimics the action of prostaglandin F by activating FP receptors on the ciliary muscle bundle and trabecular meshwork. This activation enhances drainage of aqueous humor through the unconventional uveoscleral pathway, reducing intraocular pressure. The 0.004% concentration is optimized for topical ocular delivery to achieve therapeutic effect while minimizing systemic exposure.","oneSentence":"Travoprost is a prostaglandin F analog that binds to prostaglandin F (FP) receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:01.211Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT00847483","phase":"PHASE4","title":"Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2002-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":375}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Travatan"],"phase":"marketed","status":"active","brandName":"Travoprost 004% sterile ophthalmic solution","genericName":"Travoprost 004% sterile ophthalmic solution","companyName":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","companyId":"pfizer-s-upjohn-has-merged-with-mylan-to-form-viatris-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Travoprost is a prostaglandin F analog that binds to prostaglandin F (FP) receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}